CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Warner Chilcott Plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Warner Chilcott Plc
1 Grand Canal Square
Docklands, Dublin 2
Phone: +353 18972000p:+353 18972000 DUBLIN, Ireland
This company ceased filing statements with the SEC on 10/11/2013.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Warner Chilcott Public Limited Company is a specialty pharmaceutical company. The Company is focused on the women’s healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. The Company’s hormonal contraceptive product offerings include LOESTRIN 24 FE (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), the branded product in the United States hormonal contraception market, and LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), its new oral contraceptive product, launched in January 2011, that offers women the lowest dosage of estrogen of any oral contraceptive available in the United States market. In October 2013, Actavis Inc acquired the entire share capital of Warner Chilcott PLC.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201312/31/2012YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2830 Drugs
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board John A.King 64 1/1/2011 6/20/2005
President, Chief Executive Officer, Director Roger M.Boissonneault 64 1/5/2005 1/5/2005
Chief Financial Officer, Executive Vice President, Director Paul S.Herendeen 57 5/2/2013 4/1/2005
11 additional Officers and Directors records available in full report.

Business Names
Business Name
G3LA
Warner Chilcott (Ireland) Limited
Warner Chilcott (US), LLC
5 additional Business Names available in full report.

General Information
Number of Employees: 2,100 (As of 12/31/2012)
Outstanding Shares: 251,139,194 (As of 7/1/2013)
Shareholders: 8
Stock Exchange: NASD
Federal Tax Id: 980496358


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023